stockrowAbCellera Biologics Inc. (ABCL) vs ACADIA Pharmaceuticals Inc. (ACAD)
- AbCellera Biologics Inc. ABCL 11.89 +6.83%
- ACADIA Pharmaceuticals Inc. ACAD 21.23 −0.05%
AbCellera Biologics Inc. and ACADIA Pharmaceuticals Inc. are both Biotechnology companies. AbCellera Biologics Inc. and ACADIA Pharmaceuticals Inc. are of similar size ($3.7B and $3.6B). AbCellera Biologics Inc. has negative trailing earnings, so its P/E is not meaningful; ACADIA Pharmaceuticals Inc. trades at 10.0×. AbCellera Biologics Inc. grew revenue faster over the last twelve months: 101.3% against 14.8%. ACADIA Pharmaceuticals Inc. has the higher net margin (30.1% vs −248.8%) and the higher return on invested capital (18.6% vs −42.5%). Across the 17 metrics below, ACADIA Pharmaceuticals Inc. leads on 14 and AbCellera Biologics Inc. on 3.
Valuation
Profitability
| Metric | ABCL | ACAD | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 90.48% | 65.16% |
| Operating margin | (340.25%) | 10.17% | 0.00% |
| Net margin | (248.82%) | 30.13% | 0.00% |
| Free cash flow margin | (180.84%) | 6.82% | 0.00% |
| Return on equity | (17.30%) | 31.43% | (50.12%) |
| Return on assets | (12.15%) | 23.18% | (45.60%) |
| Return on invested capital | (42.52%) | 18.60% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack